| Year |
Citation |
Score |
| 2021 |
Corona A, Blobe GC. The role of the extracellular matrix protein TGFBI in cancer. Cellular Signalling. 84: 110028. PMID 33940163 DOI: 10.1016/j.cellsig.2021.110028 |
0.367 |
|
| 2021 |
Pawlak JB, Blobe GC. TGF-β superfamily co-receptors in cancer. Developmental Dynamics : An Official Publication of the American Association of Anatomists. PMID 33797167 DOI: 10.1002/dvdy.338 |
0.448 |
|
| 2021 |
Tazat K, Pomeraniec-Abudy L, Hector-Greene M, Szilágyi SS, Sharma S, Cai EM, Corona AL, Ehrlich M, Blobe GC, Henis YI. ALK1 Regulates the Internalization of Endoglin and the type III TGF-β Receptor. Molecular Biology of the Cell. mbcE20030199. PMID 33566682 DOI: 10.1091/mbc.E20-03-0199 |
0.435 |
|
| 2019 |
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar SY, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Bolch E, Arrowood C, Liu Y, et al. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology. PMID 31444620 DOI: 10.1007/S00280-019-03916-0 |
0.335 |
|
| 2019 |
Huang JJ, Corona AL, Dunn BP, Cai EM, Prakken JN, Blobe GC. Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. Oncogene. PMID 30643193 DOI: 10.1038/S41388-018-0672-7 |
0.546 |
|
| 2018 |
Zhao F, Evans KS, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A, Siska PJ, Blobe GC, Hanks BA. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF-β Inhibitor Sequencing in Melanoma. Cancer Immunology Research. PMID 30209062 DOI: 10.1158/2326-6066.Cir-18-0086 |
0.738 |
|
| 2018 |
Tian H, Huang JJ, Golzio C, Gao X, Hector-Greene M, Katsanis N, Blobe GC. Endoglin interacts with VEGFR2 to promote angiogenesis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201700867RR. PMID 29401587 DOI: 10.1096/Fj.201700867Rr |
0.393 |
|
| 2017 |
Tian H, Ketova T, Hardy D, Xu X, Gao X, Zijlstra A, Blobe GC. Endoglin Mediates Vascular Maturation by Promoting Vascular Smooth Muscle Cell Migration and Spreading. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 28450296 DOI: 10.1161/Atvbaha.116.308859 |
0.355 |
|
| 2017 |
Gaviglio AL, Knelson EH, Blobe GC. Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28174207 DOI: 10.1096/Fj.201600828R |
0.378 |
|
| 2016 |
Huang JJ, Blobe GC. Dichotomous roles of TGF-β in human cancer. Biochemical Society Transactions. 44: 1441-1454. PMID 27911726 DOI: 10.1042/Bst20160065 |
0.557 |
|
| 2016 |
Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC. TGF-β-Induced Stromal CYR61 Promotes Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma Through Down-Regulation of the Nucleoside Transporters hENT1 and hCNT3. Carcinogenesis. PMID 27604902 DOI: 10.1093/Carcin/Bgw093 |
0.513 |
|
| 2016 |
Cribb JA, Osborne LD, Beicker K, Psioda M, Chen J, O'Brien ET, Taylor Ii RM, Vicci L, Hsiao JP, Shao C, Falvo M, Ibrahim JG, Wood KC, Blobe GC, Superfine R. An Automated High-throughput Array Microscope for Cancer Cell Mechanics. Scientific Reports. 6: 27371. PMID 27265611 DOI: 10.1038/Srep27371 |
0.35 |
|
| 2016 |
Clarke JM, Blobe GC, Strickler JH, Uronis HE, Zafar Y, Morse M, Dropkin E, Howard L, O'Neill M, Rushing CN, Niedzwiecki D, Watson H, Arrowood C, Hurwitz H. Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL). Journal of Clinical Oncology. 34: e15013-e15013. DOI: 10.1200/Jco.2016.34.15_Suppl.E15013 |
0.409 |
|
| 2016 |
Gaviglio AL, Blobe GC. Abstract 1182: Heparin-binding epidermal growth factor-like growth factor is a pro-differentiating factor in neuroblastoma Cancer Research. 76: 1182-1182. DOI: 10.1158/1538-7445.Am2016-1182 |
0.386 |
|
| 2015 |
Tazat K, Hector-Greene M, Blobe GC, Henis YI. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling. Molecular Biology of the Cell. 26: 3535-45. PMID 26269580 DOI: 10.1091/Mbc.E15-04-0203 |
0.525 |
|
| 2015 |
Pomeraniec L, Hector-Greene M, Ehrlich M, Blobe GC, Henis YI. Regulation of TGF-β receptor hetero-oligomerization and signaling by endoglin. Molecular Biology of the Cell. 26: 3117-27. PMID 26157163 DOI: 10.1091/Mbc.E15-02-0069 |
0.536 |
|
| 2015 |
Tian H, Liu J, Chen J, Gatza ML, Blobe GC. Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment. Oncogene. PMID 25823021 DOI: 10.1038/Onc.2015.13 |
0.552 |
|
| 2015 |
Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, Blobe GC, Levinson H. Erratum to: angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. Journal of Molecular Medicine (Berlin, Germany). 93: 303. PMID 25676696 DOI: 10.1007/s00109-015-1262-6 |
0.357 |
|
| 2015 |
Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, Blobe GC, Levinson H. Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. Journal of Molecular Medicine (Berlin, Germany). 93: 289-302. PMID 25345602 DOI: 10.1007/S00109-014-1211-9 |
0.428 |
|
| 2014 |
Osborne LD, Li GZ, How T, O'Brien ET, Blobe GC, Superfine R, Mythreye K. TGF-β regulates LARG and GEF-H1 during EMT to affect stiffening response to force and cell invasion. Molecular Biology of the Cell. 25: 3528-40. PMID 25143398 DOI: 10.1091/Mbc.E14-05-1015 |
0.464 |
|
| 2014 |
Gatza CE, Elderbroom JL, Oh SY, Starr MD, Nixon AB, Blobe GC. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. Neoplasia (New York, N.Y.). 16: 489-500. PMID 25077702 DOI: 10.1016/J.Neo.2014.05.008 |
0.548 |
|
| 2014 |
Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB. Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. Investigational New Drugs. 32: 851-9. PMID 24994097 DOI: 10.1007/S10637-014-0129-Y |
0.331 |
|
| 2014 |
Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. Molecular Biology of the Cell. 25: 2320-32. PMID 24966170 DOI: 10.1091/Mbc.E13-09-0524 |
0.555 |
|
| 2014 |
Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC. Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. The Journal of Clinical Investigation. 124: 3016-31. PMID 24937430 DOI: 10.1172/Jci74270 |
0.38 |
|
| 2014 |
Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC. Role of TGF-β receptor III localization in polarity and breast cancer progression. Molecular Biology of the Cell. 25: 2291-304. PMID 24870032 DOI: 10.1091/Mbc.E14-03-0825 |
0.419 |
|
| 2014 |
Knelson EH, Nee JC, Blobe GC. Heparan sulfate signaling in cancer. Trends in Biochemical Sciences. 39: 277-88. PMID 24755488 DOI: 10.1016/J.Tibs.2014.03.001 |
0.484 |
|
| 2014 |
Holtzhausen A, Golzio C, How T, Lee YH, Schiemann WP, Katsanis N, Blobe GC. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 1248-67. PMID 24308972 DOI: 10.1096/Fj.13-239178 |
0.809 |
|
| 2014 |
Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, et al. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. Investigational New Drugs. 32: 330-9. PMID 24173967 DOI: 10.1200/Jco.2011.29.15_Suppl.3586 |
0.336 |
|
| 2014 |
Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 480-9. PMID 24173543 DOI: 10.1158/1078-0432.Ccr-13-1840 |
0.365 |
|
| 2014 |
Hanks BA, Holtzhausen A, Evans K, Heid M, Blobe GC. Combinatorial TGF-β signaling blockade and anti-CTLA-4 antibody immunotherapy in a murine BRAFV600E-PTEN-/- transgenic model of melanoma. Journal of Clinical Oncology. 32: 3011-3011. DOI: 10.1200/Jco.2014.32.15_Suppl.3011 |
0.763 |
|
| 2014 |
Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC. Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma Cancer Research. 74: 2674-2674. DOI: 10.1158/1538-7445.Am2014-2674 |
0.351 |
|
| 2014 |
Medina MA, Li G, Bashirov L, Blobe G, Levinson H. Angiotensin II Stimulates Canonical TGFβ Signaling Pathway through Angiotensin Receptor 1 to Induce Granulation Tissue Contraction Journal of the American College of Surgeons. 219. DOI: 10.1016/J.Jamcollsurg.2014.07.199 |
0.361 |
|
| 2013 |
Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. The Journal of Clinical Investigation. 123: 4786-98. PMID 24216509 DOI: 10.1172/Jci69657 |
0.446 |
|
| 2013 |
Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI. A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. Cancer Medicine. 2: 316-24. PMID 23930208 DOI: 10.1002/Cam4.65 |
0.311 |
|
| 2013 |
Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari A, George A, Starr M, Nixon A, Augustine C, Beasley G, Tyler DS, ... ... Blobe GC, et al. Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. The Journal of Clinical Investigation. 123: 3925-40. PMID 23925295 DOI: 10.1172/Jci65745 |
0.785 |
|
| 2013 |
Oh SY, Knelson EH, Blobe GC, Mythreye K. The type III TGFβ receptor regulates filopodia formation via a Cdc42-mediated IRSp53-N-WASP interaction in epithelial cells. The Biochemical Journal. 454: 79-89. PMID 23750457 DOI: 10.1042/Bj20121701 |
0.449 |
|
| 2013 |
Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma Journal of Clinical Investigation. 123: 4786-4798. DOI: 10.1172/JCI69657 |
0.339 |
|
| 2013 |
Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Nixon AB, Starr MD, Mythreye K, Blobe GC. Abstract 5041: The type III TGF-beta receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. Cancer Research. 73: 5041-5041. DOI: 10.1158/1538-7445.Am2013-5041 |
0.487 |
|
| 2013 |
Meadows KL, Lee PH, Riedel RF, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Hurwitz HI. Abstract C61: Phase I Study of pazopanib in combination with the investigational hypoxia-targeted drug TH-302. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C61 |
0.314 |
|
| 2012 |
Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC. Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. The Embo Journal. 31: 3885-900. PMID 22940691 DOI: 10.1038/Emboj.2012.246 |
0.537 |
|
| 2012 |
Lee NY, Golzio C, Gatza CE, Sharma A, Katsanis N, Blobe GC. Endoglin regulates PI3-kinase/Akt trafficking and signaling to alter endothelial capillary stability during angiogenesis. Molecular Biology of the Cell. 23: 2412-23. PMID 22593212 DOI: 10.1091/Mbc.E11-12-0993 |
0.44 |
|
| 2012 |
Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC. TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells. Oncogene. 32: 1416-27. PMID 22562249 DOI: 10.1038/Onc.2012.157 |
0.527 |
|
| 2012 |
Townsend TA, Robinson JY, How T, DeLaughter DM, Blobe GC, Barnett JV. Endocardial cell epithelial-mesenchymal transformation requires Type III TGFβ receptor interaction with GIPC. Cellular Signalling. 24: 247-56. PMID 21945156 DOI: 10.1016/J.Cellsig.2011.09.006 |
0.442 |
|
| 2012 |
Hanks BA, Holtzhausen A, Gimpel P, Jamieson R, Campbell OM, Sun L, Augustine CK, Tyler DS, Osada T, Morse M, Ling LE, Lyerly HK, Blobe GC. Effect of the loss of the type III TGFβ receptor during tumor progression on tumor microenvironment: Preclinical development of TGFβ inhibition and TGFβ-related biomarkers to enhance immunotherapy efficacy. Journal of Clinical Oncology. 30: 10563-10563. DOI: 10.1200/Jco.2012.30.15_Suppl.10563 |
0.755 |
|
| 2012 |
Hanks BA, Holtzhausen A, Gimpel P, Campbell O, Jamieson R, Ling LE, Morse MA, Lyerly HK, Blobe G. Abstract 3548: Loss of the type III TGF-β receptor during cancer progression generates an immunotolerant tumor microenvironment: Translational implications for TGF-β inhibition and immunotherapy biomarker development Immunology. 72: 3548-3548. DOI: 10.1158/1538-7445.Am2012-3548 |
0.79 |
|
| 2012 |
Holtzhausen A, How T, Gersh BC, Blobe GC. Abstract 3035: Bone morphogenetic proteins signal through Smad2 and Smad3 to regulate cell migration and proliferation Cancer Research. 72: 3035-3035. DOI: 10.1158/1538-7445.Am2012-3035 |
0.808 |
|
| 2011 |
Hanks BA, Campbell OM, Lee JD, Morse M, Clay TM, Lyerly HK, Blobe GC. Role of the type III TGF-β receptor in modulating antitumor immunity during breast cancer progression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10540. PMID 28021827 DOI: 10.1200/Jco.2011.29.15_Suppl.10540 |
0.54 |
|
| 2011 |
Baranwal S, Wang Y, Rathinam R, Lee J, Jin L, McGoey R, Pylayeva Y, Giancotti F, Blobe GC, Alahari SK. Molecular characterization of the tumor-suppressive function of nischarin in breast cancer. Journal of the National Cancer Institute. 103: 1513-28. PMID 21917605 DOI: 10.1093/Jnci/Djr350 |
0.404 |
|
| 2011 |
Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia (New York, N.Y.). 13: 758-70. PMID 21847367 DOI: 10.1593/Neo.11528 |
0.814 |
|
| 2011 |
Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, Sutton L, Hurwitz HI. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. The Oncologist. 16: 1131-7. PMID 21795432 DOI: 10.1634/Theoncologist.2011-0078 |
0.348 |
|
| 2011 |
Swaminathan V, Mythreye K, O'Brien ET, Berchuck A, Blobe GC, Superfine R. Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Research. 71: 5075-80. PMID 21642375 DOI: 10.1158/0008-5472.Can-11-0247 |
0.404 |
|
| 2011 |
Lambert KE, Huang H, Mythreye K, Blobe GC. The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Molecular Biology of the Cell. 22: 1463-72. PMID 21411633 DOI: 10.1091/Mbc.E10-11-0877 |
0.507 |
|
| 2011 |
Townsend TA, Robinson JY, Deig CR, Hill CR, Misfeldt A, Blobe GC, Barnett JV. BMP-2 and TGFβ2 shared pathways regulate endocardial cell transformation. Cells, Tissues, Organs. 194: 1-12. PMID 21212630 DOI: 10.1159/000322035 |
0.499 |
|
| 2010 |
Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene. 29: 2905-15. PMID 20208565 DOI: 10.1038/Onc.2010.64 |
0.495 |
|
| 2010 |
Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human cancer. Cellular Signalling. 22: 1163-74. PMID 20153821 DOI: 10.1016/J.Cellsig.2010.01.016 |
0.618 |
|
| 2010 |
Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, Duménil D. Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood. 115: 2784-95. PMID 20124515 DOI: 10.1182/Blood-2009-09-241752 |
0.491 |
|
| 2010 |
Ray BN, Lee NY, How T, Blobe GC. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis. 31: 435-41. PMID 20042635 DOI: 10.1093/Carcin/Bgp327 |
0.551 |
|
| 2010 |
Lee JD, Hempel N, Lee NY, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis. 31: 175-83. PMID 19955393 DOI: 10.1093/Carcin/Bgp271 |
0.59 |
|
| 2010 |
Hanks BA, Lee JD, Morse M, Clay TM, Lyerly HK, Blobe GC. Role of the type III TGF-b receptor in mediating immunosuppression during breast cancer progression. Journal of Clinical Oncology. 28: 10577-10577. DOI: 10.1200/Jco.2010.28.15_Suppl.10577 |
0.463 |
|
| 2010 |
Gatza CE, Blobe GC. Abstract 3971: The type III tgf-β receptor mediates bmp signaling in normal and cancerous mammary epithelial cells Cancer Research. 70: 3971-3971. DOI: 10.1158/1538-7445.Am10-3971 |
0.531 |
|
| 2009 |
Mythreye K, Blobe GC. The type III TGFbeta receptor regulates directional migration: new tricks for an old dog. Cell Cycle (Georgetown, Tex.). 8: 3069-70. PMID 19755845 DOI: 10.4161/Cc.8.19.9419 |
0.526 |
|
| 2009 |
Lee NY, Kirkbride KC, Sheu RD, Blobe GC. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Molecular Biology of the Cell. 20: 4362-70. PMID 19726563 DOI: 10.1091/Mbc.E09-07-0539 |
0.808 |
|
| 2009 |
Lee NY, Haney JC, Sogani J, Blobe GC. Casein kinase 2beta as a novel enhancer of activin-like receptor-1 signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 3712-21. PMID 19592636 DOI: 10.1096/Fj.09-131607 |
0.554 |
|
| 2009 |
Mythreye K, Blobe GC. Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion. Cellular Signalling. 21: 1548-58. PMID 19427900 DOI: 10.1016/J.Cellsig.2009.05.001 |
0.437 |
|
| 2009 |
Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proceedings of the National Academy of Sciences of the United States of America. 106: 8221-6. PMID 19416857 DOI: 10.1073/Pnas.0812879106 |
0.586 |
|
| 2009 |
You HJ, How T, Blobe GC. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis. 30: 1281-7. PMID 19325136 DOI: 10.1093/Carcin/Bgp071 |
0.572 |
|
| 2009 |
Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2 Carcinogenesis. 30: 238-248. PMID 19056927 DOI: 10.1093/Carcin/Bgn274 |
0.799 |
|
| 2009 |
Swaminathan V, Karthikeyan M, O'Brien ET, Blobe G, Superfine R. TβRIII Restores Normal Cytoskeleton Mechanics In Ovarian Cancer Cells Biophysical Journal. 96: 521a. DOI: 10.1016/J.Bpj.2008.12.2686 |
0.523 |
|
| 2008 |
Finger EC, Lee NY, You HJ, Blobe GC. Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrin-independent/lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. The Journal of Biological Chemistry. 283: 34808-18. PMID 18845534 DOI: 10.1074/Jbc.M804741200 |
0.677 |
|
| 2008 |
Lee NY, Ray B, How T, Blobe GC. Endoglin promotes transforming growth factor beta-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. The Journal of Biological Chemistry. 283: 32527-33. PMID 18775991 DOI: 10.1074/Jbc.M803059200 |
0.807 |
|
| 2008 |
Gordon KJ, Blobe GC. Role of transforming growth factor-β superfamily signaling pathways in human disease Biochimica Et Biophysica Acta - Molecular Basis of Disease. 1782: 197-228. PMID 18313409 DOI: 10.1016/J.Bbadis.2008.01.006 |
0.806 |
|
| 2008 |
Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. Carcinogenesis. 29: 905-12. PMID 18299279 DOI: 10.1093/Carcin/Bgn049 |
0.574 |
|
| 2008 |
Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. The Journal of Biological Chemistry. 283: 7628-37. PMID 18184661 DOI: 10.1074/Jbc.M704883200 |
0.812 |
|
| 2008 |
Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis. 29: 528-35. PMID 18174241 DOI: 10.1093/Carcin/Bgm289 |
0.715 |
|
| 2008 |
Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis. 29: 252-62. PMID 17999987 DOI: 10.1093/Carcin/Bgm249 |
0.831 |
|
| 2008 |
Lambert KE, Gasparetto C, Blobe GC. The Type III Transforming Growth Factor (TGF)-β Receptor Regulates Growth, Proliferation and Adhesion in Multiple Myeloma Cells Blood. 112: 5158-5158. DOI: 10.1182/Blood.V112.11.5158.5158 |
0.543 |
|
| 2007 |
You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis. 28: 2491-500. PMID 17768179 DOI: 10.1093/Carcin/Bgm195 |
0.525 |
|
| 2007 |
Lee NY, Blobe GC. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. The Journal of Biological Chemistry. 282: 21507-17. PMID 17540773 DOI: 10.1074/Jbc.M700176200 |
0.532 |
|
| 2007 |
Hempel N, How T, Dong M, Murphy SK, Fields TA, Blobe GC. Loss of betaglycan expression in ovarian cancer: role in motility and invasion. Cancer Research. 67: 5231-8. PMID 17522389 DOI: 10.1158/0008-5472.Can-07-0035 |
0.574 |
|
| 2007 |
Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, Thomas J, Ludwig KA, Mantyh CR, Ashton J, Yu D, Hurwitz HI. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. International Journal of Radiation Oncology, Biology, Physics. 68: 472-8. PMID 17498568 DOI: 10.1016/J.Ijrobp.2007.02.001 |
0.333 |
|
| 2007 |
Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Research. 67: 1090-8. PMID 17283142 DOI: 10.1158/0008-5472.Can-06-3117 |
0.653 |
|
| 2007 |
Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of Clinical Investigation. 117: 206-17. PMID 17160136 DOI: 10.1172/Jci29293 |
0.801 |
|
| 2007 |
Turley RS, Finger EC, Fields TA, Blobe GC. 281: The Role of the Type III TGF-BETA Receptor in Prostate Cancer Journal of Urology. 177: 94-94. DOI: 10.1016/S0022-5347(18)30546-9 |
0.671 |
|
| 2006 |
Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 107: 4589-96. PMID 16484590 DOI: 10.1182/Blood-2005-10-4169 |
0.539 |
|
| 2006 |
Czito BG, Willett CG, Bendell JC, Morse MA, Tyler DS, Fernando NH, Mantyh CR, Blobe GC, Honeycutt W, Yu D, Clary BM, Pappas TN, Ludwig KA, Hurwitz HI. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 656-62. PMID 16446337 DOI: 10.1200/Jco.2005.04.1749 |
0.349 |
|
| 2006 |
Karthikeyan M, Blobe G. TGF-beta type II receptor Afcs-Nature Molecule Pages. DOI: 10.1038/Mp.A002272.01 |
0.469 |
|
| 2005 |
Kirkbride KC, Ray BN, Blobe GC. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends in Biochemical Sciences. 30: 611-21. PMID 16185874 DOI: 10.1016/J.Tibs.2005.09.003 |
0.764 |
|
| 2005 |
Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer Journal of Clinical Oncology. 23: 2078-2093. PMID 15774796 DOI: 10.1200/Jco.2005.02.047 |
0.588 |
|
| 2003 |
Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science (New York, N.Y.). 301: 1394-7. PMID 12958365 DOI: 10.1126/Science.1083195 |
0.795 |
|
| 2003 |
Kirkbride KC, Blobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opinion On Biological Therapy. 3: 251-61. PMID 12662140 DOI: 10.1517/14712598.3.2.251 |
0.813 |
|
| 2002 |
Mo J, Fang SJ, Chen W, Blobe GC. Regulation of ALK-1 signaling by the nuclear receptor LXRbeta. The Journal of Biological Chemistry. 277: 50788-94. PMID 12393874 DOI: 10.1074/jbc.M210376200 |
0.47 |
|
| 2002 |
Schiemann WP, Blobe GC, Kalume DE, Pandey A, Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. The Journal of Biological Chemistry. 277: 27367-77. PMID 12021267 DOI: 10.1074/Jbc.M200148200 |
0.549 |
|
| 2001 |
Blobe GC, Liu X, Fang SJ, How T, Lodish HF. A novel mechanism for regulating transforming growth factor β (TGF-β) signaling: Functional modulation of type III TGF-β receptor expression through interaction with the PDZ domain protein, GIPC Journal of Biological Chemistry. 276: 39608-39617. PMID 11546783 DOI: 10.1074/Jbc.M106831200 |
0.539 |
|
| 2001 |
Blobe GC, Schiemann WP, Pepin MC, Beauchemin M, Moustakas A, Lodish HF, O'Connor-McCourt MD. Functional Roles for the Cytoplasmic Domain of the Type III Transforming Growth Factor β Receptor in Regulating Transforming Growth Factor β Signaling Journal of Biological Chemistry. 276: 24627-24637. PMID 11323414 DOI: 10.1074/Jbc.M100188200 |
0.467 |
|
| 2000 |
Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease New England Journal of Medicine. 342: 1350-1358. PMID 10793168 DOI: 10.1056/Nejm200005043421807 |
0.456 |
|
| 1998 |
Blobe GC, Amrein PC. The p53 tumor suppressor gene in head and neck cancer Current Opinion in Otolaryngology & Head and Neck Surgery. 6: 129-133. DOI: 10.1097/00020840-199804000-00010 |
0.305 |
|
| 1995 |
Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Reviews. 13: 411-31. PMID 7712599 DOI: 10.1007/Bf00666107 |
0.387 |
|
| Show low-probability matches. |